115 studies found for:    EXT2
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004 AM2; EXT1(AM1); EXT2(AM2); EXT3)
Condition: Osteoporosis
Interventions: Drug: MK0822;   Dietary Supplement: Vitamin D3;   Dietary Supplement: Calcium Carbonate;   Drug: Placebo
2 Completed
Has Results
A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)
Condition: HIV Infections
Interventions: Drug: raltegravir potassium;   Drug: Comparator: Placebo
3 Terminated
Has Results
An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)
Conditions: Lung Diseases;   Pulmonary Disease, Chronic Obstructive
Interventions: Drug: MK-0873 2.5 mg;   Drug: MK-0873 1.25 mg;   Drug: MK-0873 0.75 mg;   Drug: Placebo to MK-0873;   Drug: Usual Care
4 Enrolling by invitation An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
Condition: Schizophrenia
Interventions: Drug: ALKS 9072, Low Dose;   Drug: ALKS 9072, High Dose
5 Active, not recruiting A Comprehensive Longitudinal Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Diseases in China
Condition: Type 2 Diabetes
6 Completed
Has Results
A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma
Condition: Asthma
Interventions: Biological: MEDI-528 9 mg/kg;   Other: Placebo
7 Completed A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1[AM3])
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102;   Drug: Placebo;   Drug: pioglitazone;   Drug: metformin
8 Completed
Has Results
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
Conditions: Hunter Syndrome;   Mucopolysaccharidosis II (MPS II)
Intervention: Biological: Idursulfase
9 Completed
Has Results
Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients
Condition: Type 2 Diabetes
Interventions: Drug: dapagliflozin;   Drug: Glimepiride;   Drug: metformin hydrochloride;   Drug: pioglitazone hydrochloride;   Drug: Rosiglitazone
10 Terminated
Has Results
Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: MK-0941;   Drug: Comparator: Placebo;   Biological: Lantus;   Drug: Metformin
11 Completed
Has Results
Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Dapagliflozin;   Drug: Metformin;   Drug: Sitagliptin;   Drug: Placebo
12 Completed A Study of the Efficacy and Safety of MK-4618 in Patients With Overactive Bladder (OAB) (MK-4618-008 AM3 EXT1[AM2])
Condition: Urinary Bladder, Overactive
Interventions: Drug: MK-4618 low-dose;   Drug: MK-4618 mid-low dose;   Drug: MK-4618 mid-high dose;   Drug: tolterodine ER;   Drug: Placebo for MK-4618;   Drug: Placebo for tolterodine ER;   Drug: MK-4618 high dose
13 Active, not recruiting Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Epoprostenol
14 Withdrawn Open Label Extension Study to Protocol C2/13/DR-6MP-02
Condition: Crohn's Disease
Intervention: Drug: 80 mg DR-6MP
15 Completed Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.
Condition: Focus Type 2 Diabetes Related Chronic Kidney Disease
Intervention: Behavioral: Exercise
16 Recruiting Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina
Condition: Vasospastic Angina
Intervention: Drug: Cilostazol
17 Completed
Has Results
Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared
Conditions: Hepatitis B;   Hepatitis A
Interventions: Biological: Twinrix™ Adult;   Biological: Twinrix™ Junior
18 Recruiting Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell NHL
Condition: B-cell Non-Hodgkin Lymphoma
Interventions: Drug: 0.5 mg/m2 DI-Leu16-IL2;   Drug: 1.0 mg/m2 DI-Leu16-IL2;   Drug: 2.0 mg/m2 DI-Leu16-IL2;   Drug: 4.0 mg/m2 DI-Leu16-IL2;   Drug: 6.0 mg/m2 DI-Leu16-IL2;   Drug: 8.0 mg/m2 DI-Leu16-IL2;   Drug: 10.0 mg/m2 DI-Leu16-IL2
19 Active, not recruiting FUTURE 3 Study Extension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Bosentan
20 Completed
Has Results
A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™
Condition: Hypertriglyceridemia
Intervention: Drug: Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years